Detecting and treating breast cancer resistance to EGFR inhibitors
Abstract
The application describes therapeutic compositions and methods for treating cancer. For example, therapeutic compositions and methods related to inhibition of FAM83A (family with sequence similarity 83) are provided. The application also describes methods for diagnosing cancer resistance to EGFR inhibitors. For example, a method of diagnosing cancer resistance to EGFR inhibitors by detecting increased FAM83A levels is described.
- Inventors:
- Issue Date:
- Research Org.:
- Lawrence Berkeley National Lab. (LBNL), Berkeley, CA (United States)
- Sponsoring Org.:
- USDOE
- OSTI Identifier:
- 1245595
- Patent Number(s):
- 9303088
- Application Number:
- 13/248,690
- Assignee:
- The Regents of the University of California (Oakland, CA)
- Patent Classifications (CPCs):
-
C - CHEMISTRY C07 - ORGANIC CHEMISTRY C07K - PEPTIDES
- DOE Contract Number:
- AC02-05CH11231
- Resource Type:
- Patent
- Resource Relation:
- Patent File Date: 2011 Sep 29
- Country of Publication:
- United States
- Language:
- English
- Subject:
- 60 APPLIED LIFE SCIENCES; 59 BASIC BIOLOGICAL SCIENCES
Citation Formats
Moonlee, Sun-Young, Bissell, Mina J., Furuta, Saori, Meier, Roland, and Kenny, Paraic A.. Detecting and treating breast cancer resistance to EGFR inhibitors. United States: N. p., 2016.
Web.
Moonlee, Sun-Young, Bissell, Mina J., Furuta, Saori, Meier, Roland, & Kenny, Paraic A.. Detecting and treating breast cancer resistance to EGFR inhibitors. United States.
Moonlee, Sun-Young, Bissell, Mina J., Furuta, Saori, Meier, Roland, and Kenny, Paraic A.. Tue .
"Detecting and treating breast cancer resistance to EGFR inhibitors". United States. https://www.osti.gov/servlets/purl/1245595.
@article{osti_1245595,
title = {Detecting and treating breast cancer resistance to EGFR inhibitors},
author = {Moonlee, Sun-Young and Bissell, Mina J. and Furuta, Saori and Meier, Roland and Kenny, Paraic A.},
abstractNote = {The application describes therapeutic compositions and methods for treating cancer. For example, therapeutic compositions and methods related to inhibition of FAM83A (family with sequence similarity 83) are provided. The application also describes methods for diagnosing cancer resistance to EGFR inhibitors. For example, a method of diagnosing cancer resistance to EGFR inhibitors by detecting increased FAM83A levels is described.},
doi = {},
journal = {},
number = ,
volume = ,
place = {United States},
year = {2016},
month = {4}
}
Save to My Library
You must Sign In or Create an Account in order to save documents to your library.
Works referenced in this record:
A Phase I Study of Chemically Synthesized Verotoxin (Shiga-like Toxin) Pk-Trisaccharide Receptors Attached to Chromosorb for Preventing Hemolytic-Uremic Syndrome
journal, April 1995
- Armstrong, G. D.; Rowe, P. C.; Goodyer, P.
- Journal of Infectious Diseases, Vol. 171, Issue 4
Epidermal growth factor receptor as a potential therapeutic target in triple-negative breast cancer
journal, January 2009
- Corkery, B.; Crown, J.; Clynes, M.
- Annals of Oncology, Vol. 20, Issue 5
Epidermal Growth Factor Receptor Gene Expression in Estrogen Receptor-Positive and Negative Human Breast Cancer Cell Lines
journal, March 1987
- Davidson, Nancy E.; Gelmann, Edward P.; Lippman, Marc E.
- Molecular Endocrinology, Vol. 1, Issue 3
FAM83A confers EGFR-TKI resistance in breast cancer cells and in mice
journal, September 2012
- Lee, Sun-Young; Meier, Roland; Furuta, Saori
- Journal of Clinical Investigation, Vol. 122, Issue 9